Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Roland Wolf

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|March 22, 2017
Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancerA Kenneth MacLeod, Lourdes Acosta-Jimenez, Philip J Coates, et al.
Toxicology and Applied Pharmacology|January 28, 2019
Application of hepatic cytochrome b<sub>5</sub>/P450 reductase null (HBRN) mice to study the role of cytochrome b<sub>5</sub> in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticineLindsay Reed, Radek Indra, Iveta Mrizova, et al.
Proteomics|February 26, 2003
Protein expression profiling of glutathione S-transferase pi null mice as a strategy to identify potential markers of resistance to paracetamol-induced toxicity in the liverNeil R Kitteringham, Helen Powell, Rosalind E Jenkins, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 3, 2002
Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancerGillian Smith, Francis A Carey, Julie Beattie, et al.
British Journal of Clinical Pharmacology|January 22, 2003
Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolismChristoph Sachse, Upinder Bhambra, Gillian Smith, et al.
Nature|February 2, 2017
Feedback control of AHR signalling regulates intestinal immunityChris Schiering, Emma Wincent, Amina Metidji, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 18, 2006
In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancerJean-Didier Marechal, Jinglei Yu, Simon Brown, et al.
Molecular and Cellular Biology|March 11, 2009
Cholesterol metabolism: the main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limbKaty Schmidt, Catherine Hughes, J A Chudek, et al.
Journal of Medicinal Chemistry|October 16, 2004
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibitionCarol A Kemp, Jack U Flanagan, Annamaria J van Eldik, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2025
Use of an extensively humanized mouse model to predict the risk of drug-drug interactions in patients receiving dexamethasoneJacob George, James D Chalmers, Kevin-Sebastien Coquelin, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|March 22, 2017
Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancerA Kenneth MacLeod, Lourdes Acosta-Jimenez, Philip J Coates, et al.
Toxicology and Applied Pharmacology|January 28, 2019
Application of hepatic cytochrome b<sub>5</sub>/P450 reductase null (HBRN) mice to study the role of cytochrome b<sub>5</sub> in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticineLindsay Reed, Radek Indra, Iveta Mrizova, et al.
Proteomics|February 26, 2003
Protein expression profiling of glutathione S-transferase pi null mice as a strategy to identify potential markers of resistance to paracetamol-induced toxicity in the liverNeil R Kitteringham, Helen Powell, Rosalind E Jenkins, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 3, 2002
Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancerGillian Smith, Francis A Carey, Julie Beattie, et al.
British Journal of Clinical Pharmacology|January 22, 2003
Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolismChristoph Sachse, Upinder Bhambra, Gillian Smith, et al.
Nature|February 2, 2017
Feedback control of AHR signalling regulates intestinal immunityChris Schiering, Emma Wincent, Amina Metidji, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 18, 2006
In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancerJean-Didier Marechal, Jinglei Yu, Simon Brown, et al.
Molecular and Cellular Biology|March 11, 2009
Cholesterol metabolism: the main pathway acting downstream of cytochrome P450 oxidoreductase in skeletal development of the limbKaty Schmidt, Catherine Hughes, J A Chudek, et al.
Journal of Medicinal Chemistry|October 16, 2004
Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibitionCarol A Kemp, Jack U Flanagan, Annamaria J van Eldik, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2025
Use of an extensively humanized mouse model to predict the risk of drug-drug interactions in patients receiving dexamethasoneJacob George, James D Chalmers, Kevin-Sebastien Coquelin, et al.
Pageof 16